● Recruiting

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

Condition: Breast Cancer · Sponsor: Centre Hospitalier Universitaire de Besancon

PhaseN/A

Planned participants4500

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.

This description comes directly from the study's public registry record.

Talk to the study team

Elise ROBERT · +33381219086 · e1robert@chu-besancon.fr

Diane BERTHOD · +33370632403 · dberthod@chu-besancon.fr

Always discuss trial participation with your own doctor first.

Locations (5)

CHU Besançon	Besançon, France	Recruiting
Clinique Tivoli Ducos	Bordeaux, France	Recruiting
Polyclinique Bordeaux Nord Aquitaine	Bordeaux, France	Recruiting
AP-HP - Hôpital Tenon	Paris, France	Recruiting
Centre Catalan d'Oncologie	Perpignan, France	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06185569